Abstract
Objective: To assess the efficacy of inhaled, repeat doses (28 days) of the glucocorticoid agonist GW870086.
Methods: This was a randomised, placebo-controlled, parallel group study in subjects with persistent asthma (n=135) who received GW870086 (2, 3, or 4 mg, once-daily) or placebo.
Results: Improvements in forced expiratory volume in one second (FEV1) were seen following all three doses of GW870086 relative to placebo. Mean improvements (95% confidence interval) of: 0.172 L (0.015, 0.329), 0.105 L (-0.053, 0.263) and 0.159 L (0.001, 0.316) were observed for 2 mg, 3 mg and 4 mg, respectively, at Day 28. Peak expiratory flow rate results were consistent with FEV1 and rescue medication was administered more frequently in the placebo group than all three GW870086 treatment arms.
Conclusion: This study provided a positive outcome with all doses of GW870086 demonstrating improvements in lung function compared with placebo.
Keywords: Diskhaler, glucocorticoid, inhaled corticosteroid, repeat dose.
Current Drug Therapy
Title:Efficacy of a New Selective Steroid (GW870086) in Asthma: An Adaptive, Randomised, Controlled Trial
Volume: 8 Issue: 2
Author(s): Philippe Bareille, Kelly Hardes, Jonathan Robertson, Angela Davis and Ann Allen
Affiliation:
Keywords: Diskhaler, glucocorticoid, inhaled corticosteroid, repeat dose.
Abstract: Objective: To assess the efficacy of inhaled, repeat doses (28 days) of the glucocorticoid agonist GW870086.
Methods: This was a randomised, placebo-controlled, parallel group study in subjects with persistent asthma (n=135) who received GW870086 (2, 3, or 4 mg, once-daily) or placebo.
Results: Improvements in forced expiratory volume in one second (FEV1) were seen following all three doses of GW870086 relative to placebo. Mean improvements (95% confidence interval) of: 0.172 L (0.015, 0.329), 0.105 L (-0.053, 0.263) and 0.159 L (0.001, 0.316) were observed for 2 mg, 3 mg and 4 mg, respectively, at Day 28. Peak expiratory flow rate results were consistent with FEV1 and rescue medication was administered more frequently in the placebo group than all three GW870086 treatment arms.
Conclusion: This study provided a positive outcome with all doses of GW870086 demonstrating improvements in lung function compared with placebo.
Export Options
About this article
Cite this article as:
Bareille Philippe, Hardes Kelly, Robertson Jonathan, Davis Angela and Allen Ann, Efficacy of a New Selective Steroid (GW870086) in Asthma: An Adaptive, Randomised, Controlled Trial, Current Drug Therapy 2013; 8 (2) . https://dx.doi.org/10.2174/1574885511308020001
DOI https://dx.doi.org/10.2174/1574885511308020001 |
Print ISSN 1574-8855 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3903 |
Call for Papers in Thematic Issues
Novel Therapeutic Approaches and Biomarkers for Chronic Kidney Disease (CKD)
The thematic issue on "Novel Therapeutic Approaches and Biomarkers for CKD" aims to provide a comprehensive exploration of cutting-edge strategies for the management of chronic kidney disease (CKD). This issue will delve into emerging therapeutic targets, focusing on critical aspects such as podocyte injury, endothelial dysfunction, and tubulointerstitial fibrosis, which ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Airway Neurogenic Inflammation: Clinical and Pharmacological Implications
Inflammation & Allergy - Drug Targets (Discontinued) Editorial (Thematic Issue: Emerging Formulation Design and Drug Delivery Systems for Inhaled Therapy)
Current Pharmaceutical Design Relevance of Cat and Dog Sensitization by Skin Prick Testing in Childhood Eczema and Asthma
Current Pediatric Reviews Serum Amyloid A and Its Potential Physiological / Pathological Functions - an Overview of Patents
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Tobacco, Inflammation, and Respiratory Tract Cancer
Current Pharmaceutical Design The Pentacyclic Triterpenoids in Herbal Medicines and Their Pharmacological Activities in Diabetes and Diabetic Complications
Current Medicinal Chemistry Contribution of Mast Cells to Cerebral Aneurysm Formation
Current Neurovascular Research Update on Intravenous Immunoglobulins (IVIg) Mechanisms of Action and Off- Label use in Autoimmune Diseases
Current Pharmaceutical Design Regulation of Apoptosis by SYB in HepG2 Liver Cancer Cells is Mediated by the P53/Caspase 9 Axis
Anti-Cancer Agents in Medicinal Chemistry Administration of a Synbiotic to Free-Living Elderly and Evaluation of Serum Cytokines. A Pilot Study
Current Pharmaceutical Design The Use of Vitamin D in Respiratory Diseases
Current Respiratory Medicine Reviews Intelligent Drug Delivery Systems Based on Modified Chitosan Nanoparticles
Letters in Organic Chemistry Nitric Oxide and Dietary Factors: Part I Nitric Oxide Synthesis and Action
Vascular Disease Prevention (Discontinued) Radical-Scavenging Activity, Cytotoxicity and Chemical Constituents of Euphorbia orthoclada from Madagascar
The Natural Products Journal The Effects of Curcumin on Immune Responses
Current Bioactive Compounds Potential Roles of Eosinophils in Cancer Therapy: Epidemiological Studies, Experimental Models, and Clinical Pathology
Recent Patents on Anti-Cancer Drug Discovery Neurotrophic Factors - A Tool for Therapeutic Strategies in Neurological,Neuropsychiatric and Neuroimmunological Diseases?
Current Medicinal Chemistry Editorial (Thematic Issue: Improving Cancer Clinical Research and Trials with Hispanic Populations: Training and Outreach Efforts Between Moffitt Cancer Center and the Ponce School of Medicine)
Reviews on Recent Clinical Trials SiRNA Mediated Gene Silencing: Hurdles, Strategies and Applications
Pharmaceutical Nanotechnology Progress in Elucidating the Structural and Dynamic Character of G Protein-Coupled Receptor Oligomers for Use in Drug Discovery
Current Pharmaceutical Design